Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancer

被引：0
|
作者：
Blagden, S. [1 ]
Olmos, D. [2 ]
Sharma, R. [1 ]
Barruiso, J. [2 ]
Medani, H. [1 ]
Versola, M. [3 ]
Murray, S. [3 ]
Smith, D. A. [3 ]
Dar, M. M. [3 ]
deBono, J. S. [2 ]
机构：
[1] Univ London Imperial Coll Sci Technol & Med, Dept Oncol, London, England
[2] Royal Marsden Hosp, Drug Dev Unit, Sutton, Surrey, England
[3] GlaxoSmithKline Inc, Res & Dev, Res Triangle Pk, NC USA
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：135 / 135
页数：1
相关论文
共 45 条
  • [31] Targeted inhibition of Polo-like kinase 1 by a novel small-molecule inhibitor induces mitotic catastrophe and apoptosis in human bladder cancer cells
    Zhang, Zhe
    Zhang, Guojun
    Kong, Chuize
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2017, 21 (04) : 758 - 767
  • [32] YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects
    Yongxia Zhu
    Zhihao Liu
    Yanling Qu
    Jun Zeng
    Meiqin Yang
    Xiaoyi Li
    Zhaodi Wang
    Junxiang Su
    Xueqin Wang
    Luoting Yu
    Yue Wang
    Cancer Chemotherapy and Pharmacology, 2020, 86 : 33 - 43
  • [33] Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536
    Gleixner, Karoline V.
    Ferenc, Veronika
    Peter, Barbara
    Gruze, Alexander
    Meyer, Renata A.
    Hadzijusufovic, Emir
    Cerny-Reiterer, Sabine
    Mayerhofer, Matthias
    Pickl, Winfried F.
    Sillaber, Christian
    Valent, Peter
    CANCER RESEARCH, 2010, 70 (04) : 1513 - 1523
  • [34] YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects
    Zhu, Yongxia
    Liu, Zhihao
    Qu, Yanling
    Zeng, Jun
    Yang, Meiqin
    Li, Xiaoyi
    Wang, Zhaodi
    Su, Junxiang
    Wang, Xueqin
    Yu, Luoting
    Wang, Yue
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (01) : 33 - 43
  • [35] Large-Scale Label-Free Comparative Proteomics Analysis of Polo-Like Kinase 1 Inhibition via the Small-Molecule Inhibitor BI 6727 (Volasertib) in BRAFV600E Mutant Melanoma Cells
    Cholewa, Brian D.
    Pellitteri-Hahn, Molly C.
    Scarlett, Cameron O.
    Ahmad, Nihal
    JOURNAL OF PROTEOME RESEARCH, 2014, 13 (11) : 5041 - 5050
  • [36] In vivo imaging of apoptosis induction by BI 2536, a small-molecule inhibitor of human Polo-like kinase 1 (Plk1), in human cancer xenograft models
    Krssak, M.
    Guertler, U.
    Fischer, S.
    Klaus, R.
    Steegmaier, M.
    EJC SUPPLEMENTS, 2006, 4 (12): : 143 - 144
  • [37] Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536
    Breitenbuecher, Frank
    von Pawel, Joachim
    Sebastian, Martin
    Kortsik, Cornelius
    Ting, Saskia
    Kasper, Stefan
    Wohlschlaeger, Jeremias
    Worm, Karl
    Morresi-Hauf, Alicia
    Schad, Arno
    Westerwick, Daniela
    Wehler, Beatrice
    Werner, Martin
    Munzert, Gerd
    Gaschler-Markefski, Birgit
    Schmid, Kurt W.
    Schuler, Martin
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (7-8) : 435 - 439
  • [38] Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells
    Choi, Minji
    Kim, Wootae
    Cheon, Min Gyeong
    Lee, Chang-Woo
    Kim, Ja-Eun
    CANCER LETTERS, 2015, 357 (02) : 591 - 601
  • [39] A Phase II study of the polo-like kinase (PLK1) inhibitor onvansertib in combination with abiraterone (abi) and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Einstein, David J.
    Choudhury, Atish
    Saylor, Philip
    Werner, Lillian
    Erlander, Mark
    Ridinger, Maya
    Bubley, Glenn
    CANCER RESEARCH, 2019, 79 (13)
  • [40] Integrating Pharmacogenomics Data-Driven Computational Drug Prediction with Single-Cell RNAseq to Demonstrate the Efficacy of a NAMPT Inhibitor against Aggressive, Taxane-Resistant, and Stem-like Cells in Lethal Prostate Cancer
    Mazumder, Suman
    Mitra Ghosh, Taraswi
    Mukherjee, Ujjal K.
    Chakravarti, Sayak
    Amiri, Farshad
    Waliagha, Razan S.
    Hemmati, Farnaz
    Mistriotis, Panagiotis
    Ahmed, Salsabil
    Elhussin, Isra
    Salam, Ahmad-Bin
    Dean-Colomb, Windy
    Yates, Clayton
    Arnold, Robert D.
    Mitra, Amit K.
    CANCERS, 2022, 14 (23)
12345